Altratech has finalized a funding round of 5 million euros led with the Bank of Ireland Kernel Capital Growth Fund and Infinity Capital each investing 1.5 million euros.

Enterprise Ireland has also invested € 500,000 and Claret Capital is providing a risk credit facility of € 1.5 million as part of the investment round.

The company started life at the University of Limerick and is currently developing the next generation of molecular detection.

“Our team of 20 scientists and engineers have been developing our next-generation molecular sensing since 2016 and have built an extensive patent portfolio, with key patents granted in 2020 in the US and EU on our capacitive solid-state sensing. , our sample preparation and our bead tie. “said Tara Dalton, CEO of Altratech.

“Seven other patents are pending in China, Japan, Europe and the United States, including a patent filed jointly with the National Institute of Health US. This investment follows previous investments and our H2020 grants underpin the company’s scientific discoveries, ”she added.

“We need to take molecular diagnostics out of the clinical setting, and current methodologies have significant limitations to achieve this. Altratech’s patented solution can be used by anyone in any environment offering superior sensitivity and specificity. and compatible with any molecular target, ”Denise Sidhu, partner at Kernel Capital, said.

“Altratech is a deep research company led by a seasoned team with a strong track record of success. Enterprise Ireland is proud to support this cutting edge health research which has the capacity to make a positive difference globally, ”Leo Clancy, Managing Director of Enterprise Ireland said today.

“Seven other patents are pending in China, Japan, Europe and the United States, including a patent filed jointly with the National Institute of Health US. This investment follows previous investments and our H2020 grants underpin the company’s scientific discoveries, ”she added.

“We need to take molecular diagnostics out of the clinical setting, and current methodologies have significant limitations in achieving this,” said Denise Sidhu, partner at Kernel Capital.

“Altratech’s patented solution can be used by anyone in any environment offering superior sensitivity and specificity and compatible with any molecular target,” she added.

“Altratech is a deep research company led by a seasoned team with a strong track record of success. Enterprise Ireland is proud to support this cutting edge health research which has the capacity to make a positive difference globally, ”Leo Clancy, Managing Director of Enterprise Ireland said today.